| P50 | author | Ole Petter Veiby | Q95948918 |
| P2093 | author name string | Qin Zhang | |
| | Jason Yano | |
| | Kathleen Aertgeerts | |
| | Saurabh Menon | |
| | Yuan Tian | |
| | Mi-Sook Kim | |
| | Hongbo Zeng | |
| | Christopher Blackburn | |
| | Sharmila Adhikari | |
| | Tianlin Xu | |
| | Jouhara Chouitar | |
| | Ruth Adams | |
| | Ribo Guo | |
| | Shih-Chung Huang | |
| | Dong Mei Zhang | |
| | Mansoureh Rezaei | |
| | Michael D. Smith | |
| | Li-Ting Ma | |
| | Khristofer Garcia | |
| | Hirotake Mizutani | |
| | Jeffery Gaulin | |
| | Roushan Afroze | |
| | Bheemashankar Kulkarni | |
| | Juliet Williams | |
| | Alexandra E. Gould | |
| | Stepan Vyskocil | |
| | Ryan Chau | |
| | Cheryl Farrer | |
| | Dave Janowick | |
| | Erin Paske | |
| | Ming Tregay | |
| | Nancy Forsyth | |
| | Natalia Iartchouk | |
| | Stephen G. Stroud | |
| | Steven P. Langston | |
| | R. Scott Rowland | |
| | Johnny J. Yang | |
| | Paul D. Greenspan | |
| | Jane X. Liu | |
| | Michael D. Sintchak | |
| | Christelle C. Renou | |
| | Dylan B. England | |
| | Emily F. Calderwood | |
| | Katherine M. Galvin | |
| | Matthew O. Duffey | |
| | Sean J. Harrison | |
| | Tricia J. Vos | |
| P2860 | cites work | The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner | Q21629049 |
| | Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma | Q24597152 |
| | Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity | Q24652600 |
| | Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885 | Q27643208 |
| | Mutations of the BRAF gene in human cancer | Q27860760 |
| | Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF | Q28251989 |
| | Efficient Asymmetric Synthesis of the Four Diastereomers of Diphenacoum and Brodifacoum | Q29037036 |
| | BRAF mutation predicts sensitivity to MEK inhibition | Q29614281 |
| | BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis | Q29617585 |
| | Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer | Q29618155 |
| | Mitogen-activated protein kinase pathways | Q29618431 |
| | Melanoma biology and new targeted therapy | Q36742015 |
| | BRAF as therapeutic target in melanoma | Q37720832 |
| | RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models | Q39692674 |
| | AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl | Q40093939 |
| | Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature | Q40270911 |
| | Synthesis of novel melanocortin 4 receptor agonists and antagonists containing a succinamide core | Q44708040 |
| | Comparison between polyethylenglycol and imidazolium ionic liquids as solvents for developing a homogeneous and reusable palladium catalytic system for the Suzuki and Sonogashira coupling | Q63887569 |
| | Correlation of growth capacity of human tumor cells in hard agarose with their in vivo proliferative capacity at specific metastatic sites | Q69725710 |
| | Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis | Q80372711 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1836-46 | |
| P577 | publication date | 2011-02-22 | |
| | 2011-03-24 | |
| P1433 | published in | Journal of Medicinal Chemistry | Q900316 |
| P1476 | title | Design and optimization of potent and orally bioavailable tetrahydronaphthalene Raf inhibitors | |
| | Design and Optimization of Potent and Orally Bioavailable Tetrahydronaphthalene Raf Inhibitors | |
| P478 | volume | 54 | |